PDF(Pubmed)
Abstract：
UNASSIGNED: This phase 2 study evaluated the safety of adjuvant chemoradiation (CTRT) for breast cancer.
UNASSIGNED: From April 2019 to 2020, 60 patients with stage II-III invasive breast cancer planned for adjuvant taxane-based chemotherapy and radiotherapy (RT) were accrued. Local ± regional (excluding the internal mammary nodal region) RT (40 Gy in 15 fractions ± boost) was started with the third cycle of an adjuvant taxane in a 3-weekly schedule or with the eighth cycle in a weekly schedule.
UNASSIGNED: Thirty-six patients received 3-weekly paclitaxel regimen and 24 received weekly paclitaxel regimen. The commonly used technique was three-dimensional conformal RT which was employed in 58% of patients. Regional RT, including the medial supraclavicular region, was done in 42 patients (70%). No dose-limiting (grade 3 or 4) toxicity was documented and all patients completed CTRT without any treatment interruption. The median ejection fraction pre and post CTRT 6 months was 60% (p = 0.177). The median value of cardiac enzyme (Troponin T ng/L) decreased from 37 to 20 (p = 0.009) post CTRT 6 months. Of the 54 patients who underwent the pulmonary function tests, there was no significant difference in various parameters like functional vital capacity (FVC) (2.29 versus 2.2 L, p = 0.375), forced expiratory volume at 1 second (FEV1) (1.86; 1.82; p = 0.365), FEV1/FVC (81.5; 81.43; p = 0.9) and diffusion lung capacity for carbon monoxide (88.3; 87.6; p = 0.62). At a median follow-up of 34 months, the 3-year actuarial rate of disease-free survival and overall survival was 75% and 98.3%, respectively. Quality of life scores (QOL) improved after treatment for most of the domains comparable to the pre-RT scores.
UNASSIGNED: Taxane-based adjuvant CTRT is a safe option and results in minimal toxicity and excellent compliance. It has favourable impact on cardio-pulmonary profile and QOL scores.
UNASSIGNED: From April 2019 to 2020, 60 patients with stage II-III invasive breast cancer planned for adjuvant taxane-based chemotherapy and radiotherapy (RT) were accrued. Local ± regional (excluding the internal mammary nodal region) RT (40 Gy in 15 fractions ± boost) was started with the third cycle of an adjuvant taxane in a 3-weekly schedule or with the eighth cycle in a weekly schedule.
UNASSIGNED: Thirty-six patients received 3-weekly paclitaxel regimen and 24 received weekly paclitaxel regimen. The commonly used technique was three-dimensional conformal RT which was employed in 58% of patients. Regional RT, including the medial supraclavicular region, was done in 42 patients (70%). No dose-limiting (grade 3 or 4) toxicity was documented and all patients completed CTRT without any treatment interruption. The median ejection fraction pre and post CTRT 6 months was 60% (p = 0.177). The median value of cardiac enzyme (Troponin T ng/L) decreased from 37 to 20 (p = 0.009) post CTRT 6 months. Of the 54 patients who underwent the pulmonary function tests, there was no significant difference in various parameters like functional vital capacity (FVC) (2.29 versus 2.2 L, p = 0.375), forced expiratory volume at 1 second (FEV1) (1.86; 1.82; p = 0.365), FEV1/FVC (81.5; 81.43; p = 0.9) and diffusion lung capacity for carbon monoxide (88.3; 87.6; p = 0.62). At a median follow-up of 34 months, the 3-year actuarial rate of disease-free survival and overall survival was 75% and 98.3%, respectively. Quality of life scores (QOL) improved after treatment for most of the domains comparable to the pre-RT scores.
UNASSIGNED: Taxane-based adjuvant CTRT is a safe option and results in minimal toxicity and excellent compliance. It has favourable impact on cardio-pulmonary profile and QOL scores.
摘要：
■这项2期研究评估了乳腺癌辅助放化疗（CTRT）的安全性。
■从2019年4月至2020年，计划接受基于紫杉烷的辅助化疗和放疗（RT）的60例II-III期浸润性乳腺癌患者。局部±区域（不包括内部乳腺结节区域）RT（15个分数中的40Gy±加强）从辅助紫杉烷的第三个周期开始，每周一次，每周一次。
■36例患者接受3周紫杉醇方案，24例接受每周紫杉醇方案。常用的技术是三维适形RT，在58％的患者中采用。RegionalRT,包括锁骨上内侧区域，42例患者（70%）。没有记录剂量限制性(3级或4级)毒性,并且所有患者完成CTRT而没有任何治疗中断。CTRT前后6个月的射血分数中位数为60%(p=0.177)。CTRT6个月后，心肌酶（肌钙蛋白Tng/L）的中位数从37降至20（p=0.009）。在接受肺功能检查的54名患者中，功能肺活量（FVC）等各种参数没有显着差异（2.29对2.2L，p=0.375),1秒用力呼气量（FEV1）（1.86；1.82；p=0.365），FEV1/FVC(81.5;81.43;p=0.9)和一氧化碳弥散肺活量(88.3;87.6;p=0.62)。中位随访34个月,无病生存率和总生存率的3年精算率为75％和98.3％，分别。治疗后，大多数领域的生活质量评分（QOL）与RT前评分相当。
■基于紫杉烷的佐剂CTRT是一种安全的选择，具有最小的毒性和出色的依从性。它对心肺特征和QOL评分有有利的影响。
■从2019年4月至2020年，计划接受基于紫杉烷的辅助化疗和放疗（RT）的60例II-III期浸润性乳腺癌患者。局部±区域（不包括内部乳腺结节区域）RT（15个分数中的40Gy±加强）从辅助紫杉烷的第三个周期开始，每周一次，每周一次。
■36例患者接受3周紫杉醇方案，24例接受每周紫杉醇方案。常用的技术是三维适形RT，在58％的患者中采用。RegionalRT,包括锁骨上内侧区域，42例患者（70%）。没有记录剂量限制性(3级或4级)毒性,并且所有患者完成CTRT而没有任何治疗中断。CTRT前后6个月的射血分数中位数为60%(p=0.177)。CTRT6个月后，心肌酶（肌钙蛋白Tng/L）的中位数从37降至20（p=0.009）。在接受肺功能检查的54名患者中，功能肺活量（FVC）等各种参数没有显着差异（2.29对2.2L，p=0.375),1秒用力呼气量（FEV1）（1.86；1.82；p=0.365），FEV1/FVC(81.5;81.43;p=0.9)和一氧化碳弥散肺活量(88.3;87.6;p=0.62)。中位随访34个月,无病生存率和总生存率的3年精算率为75％和98.3％，分别。治疗后，大多数领域的生活质量评分（QOL）与RT前评分相当。
■基于紫杉烷的佐剂CTRT是一种安全的选择，具有最小的毒性和出色的依从性。它对心肺特征和QOL评分有有利的影响。
